{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:31:14Z","timestamp":1791117074933,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2007,10,12]]},"DOI":"10.1007\/s11864-007-0026-0","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T20:03:38Z","timestamp":1186430618000},"page":"109-116","source":"Crossref","is-referenced-by-count":15,"title":["Splenic marginal zone lymphoma with and without villous lymphocytes"],"prefix":"10.1007","volume":"8","author":[{"given":"Estella","family":"Matutes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,7]]},"reference":[{"key":"26_CR1","unstructured":"Isaacson PG, Piris MA, Catovsky D, et\u00a0al.: Splenic marginal zone cell lymphoma. In: Jaffe ES, Harris N, Vardiman JW editors. Tumours of Haemopoietic and lymphoid tissues. World Health Organization Classification of tumours Lyon, France: IARC Press; 2001, 135\u2013137"},{"key":"26_CR2","unstructured":"Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes\/splenic marginal zone lymphoma. Semin Hematol 1999, 36:148\u2013154"},{"key":"26_CR3","doi-asserted-by":"crossref","unstructured":"Arcani L Paulli M, Boveri E, et\u00a0al.: Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic features. Cancer 2004, 100:107\u2013115","DOI":"10.1002\/cncr.11893"},{"key":"26_CR4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","volume":"102","author":"A Mele","year":"2003","unstructured":"Mele A, Pulsoni A, Bianco E, et\u00a0al.: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102:996\u2013999.","journal-title":"Blood"},{"key":"26_CR5","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood.V84.11.3828.bloodjournal84113828","volume":"84","author":"PG Isaacson","year":"1994","unstructured":"Isaacson PG, Matutes E, Burke M, Catovsky D The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994, 84:3828\u20133834.","journal-title":"Blood"},{"key":"26_CR6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0002-9440(10)65411-9","volume":"154","author":"M Mateo","year":"1999","unstructured":"Mateo M, Mollejo M, Villuendas R, et\u00a0al.: 7q31\u201332 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999, 154:1583\u20131589.","journal-title":"Am J Pathol"},{"key":"26_CR7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.1999.01209.x","volume":"104","author":"AM Gruszka-Westwood","year":"1999","unstructured":"Gruszka-Westwood AM, Matutes E, Coignet LJA, et\u00a0al.: The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol 1999;104:600\u2013604.","journal-title":"Br J Haematol"},{"key":"26_CR8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood.V97.11.3552","volume":"97","author":"AM Gruszka-Westwood","year":"2003","unstructured":"Gruszka-Westwood AM, Hamoudi RA, Matutes E, et\u00a0al.: p53 abnormalities in splenic lymphoma with villous lymphocytes (SLVL). Blood 2003; 97:3552\u20133558.","journal-title":"Blood"},{"key":"26_CR9","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Felman P, Callet-Bauchu E, et\u00a0al.: Splenic marginal zone lymphoma: a distinct clinical and pathological entity. The Lancet Oncol 2003; 4:95\u2013103","DOI":"10.1016\/S1470-2045(03)00981-1"},{"key":"26_CR10","doi-asserted-by":"crossref","unstructured":"Arcaini L, Lazzarino M, Colombo N et\u00a0al.: Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006, 107:4643\u20134649","DOI":"10.1182\/blood-2005-11-4659"},{"key":"26_CR11","doi-asserted-by":"crossref","unstructured":"Chacon J, Mollejo M, Munoz E et\u00a0al.: Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002, 100:1648\u20131654","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654"},{"key":"26_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","volume":"93","author":"X Troussard","year":"1996","unstructured":"Troussard X, Valensi F, Duchayne E, et\u00a0al.: Splenic lymphoma with villous lymphocytes. Clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996; 93:731\u2013736.","journal-title":"Br J Haematol."},{"key":"26_CR13","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","volume":"101","author":"E Iannitto","year":"2004","unstructured":"Iannitto E, Ambrosetti A, Ammatuna E, et\u00a0al.: Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101:2050\u20132057.","journal-title":"Cancer"},{"key":"26_CR14","doi-asserted-by":"crossref","unstructured":"Parry-Jones N, Matutes E, Gruszka-Westwood AM, et\u00a0al.: Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003, 120: 759\u2013764","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"26_CR15","doi-asserted-by":"crossref","unstructured":"Camacho FI, Mollejo M, Mateo MS, et\u00a0al.: Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001, 25:1268\u20131276","DOI":"10.1097\/00000478-200110000-00007"},{"key":"26_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","volume":"78","author":"SP Mulligan","year":"1991","unstructured":"Mulligan SP, Matutes E, Dearden C, et\u00a0al.: Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206\u2013209.","journal-title":"Br J Haematol"},{"key":"26_CR17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","volume":"91","author":"V Franco","year":"2001","unstructured":"Franco V, Florena AM, Stella M, et\u00a0al.: Splenectomy influences bone marrow infiltration in patients with splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2001; 91:294\u2013301.","journal-title":"Cancer"},{"key":"26_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2141.1997.3523168.x","volume":"99","author":"S Bolam","year":"1997","unstructured":"Bolam S, Orchard J, Oscier D: Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99:158\u2013161.","journal-title":"Br J Haematol"},{"key":"26_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1600-0609.2002.02759.x","volume":"69","author":"M Yasukawa","year":"2002","unstructured":"Yasukawa M, Yamaguchi H, Azuma T, et al.: Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol 2002; 69:112\u2013114.","journal-title":"Eur J Haematol"},{"key":"26_CR20","doi-asserted-by":"crossref","unstructured":"Lefrere F, Levy V, Francois S, et\u00a0al.: Fludarabine treatment in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia 2004, 18:1924\u20131925","DOI":"10.1038\/sj.leu.2403440"},{"key":"26_CR21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.1998.0636f.x","volume":"100","author":"A Virchis","year":"1998","unstructured":"Virchis A, Mehta A: Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CDA). Br J Haematol 1998; 100:609.","journal-title":"Br J Haematol"},{"key":"26_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.717","volume":"21","author":"R Riccioni","year":"2003","unstructured":"Riccioni R, Caracciolo F, Galimberti S, et\u00a0al.: Low dose 2-CDA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21:163\u2013168.","journal-title":"Hematol Oncol"},{"key":"26_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428190009054887","volume":"40","author":"F Lefrere","year":"2000","unstructured":"Lefrere F, Hermine O, Francois S, et\u00a0al.: Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000, 40:113\u2013117.","journal-title":"Leuk Lymphoma"},{"key":"26_CR24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0268-960X(96)90022-3","volume":"10","author":"A Delanoy","year":"1996","unstructured":"Delanoy A: 2 chlorodeoxyadenosine: clinical applications in hematology. Blood Rev 1996, 10:148\u2013166.","journal-title":"Blood Rev"},{"key":"26_CR25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","volume":"75","author":"E Iannitto","year":"2005","unstructured":"Iannitto E, Minardi V, Calvaruso G, et\u00a0al.: Deoxycoformycin (penttostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005, 75:130\u2013135.","journal-title":"Eur J Haematol"},{"key":"26_CR26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","volume":"6","author":"A Fabbri","year":"2006","unstructured":"Fabbri A, Gozetti A, Lazzi S, et\u00a0al.: Activity of rituximab in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006, 6:496\u2013499.","journal-title":"Clin Lymphoma Myeloma"},{"key":"26_CR27","unstructured":"Bennett M, Sharma K, Yegena S, et\u00a0al.: Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005, 90:856\u2013858"},{"key":"26_CR28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3816\/CLM.2004.n.005","volume":"4","author":"L Arcaini","year":"2004","unstructured":"Arcaini L, Orlandi E, Scotti M, et\u00a0al.: Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004; 4:250\u2013252.","journal-title":"Clin Lymphoma"},{"key":"26_CR29","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Catovsky D, Schlette E, et\u00a0al.: Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006, 107:125\u2013135","DOI":"10.1002\/cncr.21931"},{"key":"26_CR30","doi-asserted-by":"crossref","unstructured":"Hermine O, Lefrere F, Bronowicki JP, et\u00a0al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89\u201394","DOI":"10.1056\/NEJMoa013376"},{"key":"26_CR31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","volume":"23","author":"D Vallisa","year":"2005","unstructured":"Vallisa D, Bernuzzi P, Arcaini L, et\u00a0al.: Role of anti-hepatitis C virus (HCV) treatment in HCV-related low grade B-cell non-Hodgkin\u2019s lymphoma: A muticenter Italian Experience. J Clin Oncol 2005, 23:468\u2013473.","journal-title":"J Clin Oncol"},{"key":"26_CR32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","volume":"18","author":"C Keladi","year":"2004","unstructured":"Keladi C, Rollor F, Park S, et\u00a0al.: Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia 2004, 18:1711\u20131716.","journal-title":"Leukemia"},{"key":"26_CR33","first-page":"1435","volume":"90","author":"NC Osuji","year":"2005","unstructured":"Osuji NC, del Guidice I, Matutes E, et\u00a0al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90:1435\u20131436.","journal-title":"Haematologica"},{"key":"26_CR34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","volume":"82","author":"PD Thornton","year":"2003","unstructured":"Thornton PD, Matutes E, Bosanquet AG, et\u00a0al.: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann. Haematol 2003; 82:759\u2013765.","journal-title":"Ann. Haematol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-007-0026-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0026-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T17:13:12Z","timestamp":1587834792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-007-0026-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s11864-007-0026-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]}}}